Gastric cancer cells can activate KRAS-driven signals, enabling autonomous tumor growth by producing their own WNT proteins. New research reveals how gastric cancer cells exploit WNT signaling for growth, revealing potential treatment targets to combat this deadly disease.

Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape drug-induced quiescence through a nongenetic manner of ...

Yeast filamentous growth is a highly regulated cellular differentiation response, enabling cells to assume an elongated morphology when confronted with environmental stress or nutrient limitation. Central to this process is the modulation of mitogen ...

Gastric (stomach) cancer remains one of the most common and deadly cancers in East Asia, including Korea. Yet despite its high prevalence, it has received far less molecular attention than colorectal cancer,

RAMP 203 is a Phase 1/2 clinical trial being conducted in collaboration with Amgen evaluating avutometinib, an oral RAF/MEK clamp, and LUMAKRAS™ (sotorasib) in a “doublet combination” and also with defactinib, an oral FAK inhibitor, as a “triplet combination” in patients naïve to or previously treated with a KRAS G12C inhibitor.

Midline Low-Grade Gliomas of Early Childhood: Focus on Targeted Therapies As there were no previous pediatric data, ulixertinib was initially tested in a dose escalation cohort to establish the recommended phase II dose (RP2D) before proceeding to the ...